RyboDyn Joins Lilly Gateway Labs to Advance Immunotherapies
June 20, 2025
Lilly Collaboration Accelerates RyboDyn’s Dark Proteome Targets Toward First-in-Class Therapies RyboDyn, a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, announced its selection to